Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Real-World Effectiveness Data on Mild and Moderate Hemophilia a Patients Using Bay 81-8973 in the Athndataset

Martin Chandler, Jessica Charlet, Tammuella Chrisentery-Singleton

Blood (2024) 144 (Supplement 1): 5480.

https://doi.org/10.1182/blood-2024-206078

Published: 2024

Journal Articles

Real-World Data on Hemophilia a Patient Usage of Bay 81-8973 and Bay 94-9027 Stratified By Body Mass Index Categories in the Athndataset

Martin Chandler, Jessica Charlet, Tammuella Chrisentery-Singleton

Blood (2024) 144 (Supplement 1): 2593.

https://doi.org/10.1182/blood-2024-198690

Published: 2024

Journal Articles

ATHN Transcends Hemophilia Natural History Arm: Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia A and B

Fernando F Corrales-Medina, Nana Ama Afari-Dwamena, Amanda B. Blair, Shannon L Carpenter, Tammuella Chrisentery-Singleton, Nabil Daoud, Maissaa Janbain, Leslie Raffini, Jonathan Schwartz, Ayesha Zia, Michael Recht

Blood (2024) 144 (Supplement 1): 1204.

https://doi.org/10.1182/blood-2024-198548

Published: 2024

Journal Articles

Athn 10 - Novel Variants in Persons with Rare Coagulation Disorders across Hemophilia Treatment Centers in the United States

Diane J. Nugent, Shirley Williams, Suchitra Acharya, Christina Ashburner, Vinod V. Balasa, Nidhi Bhatt, Martin Chandler, Tammuella Chrisentery-Singleton, Nicole Crook, Hilda Ding, Carol Fedor, Ravitharan Krishnadasan, Jonathan C. Roberts, Beverly Schaefer, Ayesha Zia, Amy D. Shapiro

Blood (2024) 144 (Supplement 1): 1216.

https://doi.org/10.1182/blood-2024-201837

Published: 2024

Journal Articles

Continuous Prophylaxis with Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Types 1 and 2 Von Willebrand Disease in a Real-World Setting: Interim Analysis of Athn 9, a Natural History Study for People with Severe VWD

Robert F Sidonio, Jr., Angela C Weyand, Tammuella Chrisentery-Singleton, Martin Chandler, Carol Fedor, Priscilla Driscoll-Shempp, Michelle Kirby, Jorge Caicedo

Blood (2024) 144 (Supplement 1): 2594.

https://doi.org/10.1182/blood-2024-200261

Published: 2024

Journal Articles

Low Rebleed Incidence with Eptacog Beta Treatment through 24 and 48 Hours in Children (<12 years) with Hemophilia a or B with Inhibitors

Blood (2023) 142 (Supplement 1): 5480.

https://doi.org/10.1182/blood-2023-181299

Published: 2023

Journal Articles

Real-World Use of Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe VWD

Robert F. Sidonio, Angela C Weyand, Tammuella Chrisentery-Singleton, Martin Chandler, Haduwa Momoh, Priscilla Driscoll-Shempp, Bethany Jones, Natalia Nieto, Jorge Caicedo

Blood (2023) 142 (Supplement 1): 2613.

https://doi.org/10.1182/blood-2023-174729

Published: 2023

Journal Articles

Athn Transcends Natural History Cohort Study of Bleeding Symptoms and Treatment Outcomes in Patients with Glanzmann Thrombasthenia

Tammuella Chrisentery-Singleton, Carrie O'Neill, Catherine Rea, Jigar Amin, Michael Recht

Blood (2023) 142 (Supplement 1): 5457.

https://doi.org/10.1182/blood-2023-190090

Published: 2023

Journal Articles

Long-Term Follow-up of Patients with Congenital Thrombotic Thrombocytopenia Purpura Receiving Plasma-Derived Factor VIII Containing (Koate®)

Tammuella Chrisentery-Singleton, Lisa N Boggio, Manuel Carcao, Sami Ibrahimi, Osman Khan, Arash Mahajerin, Anita Rajasekhar, Vivek Sharma, MacGregor Steele, Marcela Torres, Shannon L Carpenter

Blood (2022) 140 (Supplement 1): 5644–5646.

https://doi.org/10.1182/blood-2022-162506

Published: 2022

Journal Articles

A Preliminary Analysis of Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors

Tammuella Chrisentery-Singleton, Lauren E. Amos, Daniel Bonzo, Miguel Escobar, Adam Giermasz, Emmanuelle Lagrue, Christine Knoll, Sonia Nasr, Michael Recht, Spencer Sullivan, Doris V. Quon, Mark T. Reding

Blood (2022) 140 (Supplement 1): 11360–11361.

https://doi.org/10.1182/blood-2022-163372

Published: 2022

Journal Articles

Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors

Amy L. Dunn, Yesim Dargaud, Yasmina L. Abajas, Manuel Carcao, Giancarlo Castaman, Adam Giermasz, Cédric Hermans, Magdalena D. Lewandowska, Johnny Mahlangu, Shannon L. Meeks, Wolfgang A. Miesbach, Michael Recht, Vanessa Salinas, Tammuella Chrisentery-Singleton, Hongying Wang, Ian S Mitchell, Guy Young

Blood (2022) 140 (Supplement 1): 8485–8488.

https://doi.org/10.1182/blood-2022-157343

Published: 2022

Journal Articles

Reduced Dosing Frequency Following a Switch to Rix-FP for the Treatment of Hemophilia B: Results from the Athn 2 Study

Janna Journeycake, Dunlei Cheng, Tammuella Chrisentery-Singleton, Vidhi Desai, Annette von Drygalski, Carol Fedor, Nikki Hirsh, Birju Patel, Leslie J. Raffini, Michael Recht, Robert F. Sidinio, Jr., Michael Wang, Xiang Zhang, Ellis J. Neufeld

Blood (2021) 138 (Supplement 1): 1039.

https://doi.org/10.1182/blood-2021-144617

Published: 2021

Journal Articles

Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age

Blood (2021) 138 (Supplement 1): 3195.

https://doi.org/10.1182/blood-2021-147434

Published: 2021

Journal Articles

Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors with or without Prophylactic Treatment

Tammuella Chrisentery-Singleton, W Allan Alexander, Ahmad Al-Sabbagh, Daniel Bonzo, Michael U. Callaghan, Miguel A. Escobar, Adam Giermasz, Nikki Hirsh, Janna Journeycake, Sonia Nasr, Doris V. Quon, Michael Recht

Blood (2021) 138 (Supplement 1): 3201.

https://doi.org/10.1182/blood-2021-146247

Published: 2021

NARROW

Real-World Effectiveness Data on Mild and Moderate Hemophilia a Patients Using Bay 81-8973 in the Athndataset

Real-World Data on Hemophilia a Patient Usage of Bay 81-8973 and Bay 94-9027 Stratified By Body Mass Index Categories in the Athndataset

ATHN Transcends Hemophilia Natural History Arm: Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia A and B

Athn 10 - Novel Variants in Persons with Rare Coagulation Disorders across Hemophilia Treatment Centers in the United States

Continuous Prophylaxis with Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Types 1 and 2 Von Willebrand Disease in a Real-World Setting: Interim Analysis of Athn 9, a Natural History Study for People with Severe VWD

Low Rebleed Incidence with Eptacog Beta Treatment through 24 and 48 Hours in Children (<12 years) with Hemophilia a or B with Inhibitors

Real-World Use of Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe VWD

Athn Transcends Natural History Cohort Study of Bleeding Symptoms and Treatment Outcomes in Patients with Glanzmann Thrombasthenia

Long-Term Follow-up of Patients with Congenital Thrombotic Thrombocytopenia Purpura Receiving Plasma-Derived Factor VIII Containing (Koate®)

A Preliminary Analysis of Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors

Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors

Reduced Dosing Frequency Following a Switch to Rix-FP for the Treatment of Hemophilia B: Results from the Athn 2 Study

Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age

Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors with or without Prophylactic Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only